Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
22 participants
OBSERVATIONAL
2008-06-30
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-term Safety and Tolerability of AFFITOPE AD02
NCT00711321
AD01 Follow up Extension Visit
NCT01225809
Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02
NCT01093664
Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005A
NCT01568086
Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease
NCT01117818
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
AFFITOPE AD01
No interventions assigned to this group
2
AFFITOPE AD01 + Adjuvant
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients having participated in AFFiRiS 001 and received at least 1 vaccination with AFFITOPE AD01
* Availability of a partner/caregiver knowing the patient and being able to accompany the patient to the visits.
Exclusion Criteria
* Contraindication for MRI imaging
* History of questionable compliance to visit schedule, patients not expected to complete the clinical trial
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Affiris AG
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Markus Mueller, Univ. Prof.
Role: PRINCIPAL_INVESTIGATOR
Medical University of Vienna
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Clinical Pharmacology, Medical University of Vienna
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EudraCT 2008-001455-22
Identifier Type: -
Identifier Source: secondary_id
Affiris 003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.